开发和性能评价自组装的适应pH值的黄素-细菌外聚糖菌结合物作为生物活性输送系统
Chandrika Gupta1, Chinmay Hazra1, Puja Poddar2
1Department of Biotechnology, Indian Institute of Technology Kharagpur, West Bengal, India.
International journal of biological macromolecules
|February 23, 2024
概括
研究人员开发了黄素-外聚糖 (EPS) 结合物,以增强黄素的作用.
科学领域:
- 生物材料科学 生物材料科学
- 药物输送系统 药物输送系统
- 纳米技术纳米技术
背景情况:
- 黄素 (Cur) 是一种具有有限生物可用性的生物活性化合物.
- 细菌外聚糖 (EPS) 为药物输送提供了一个生物相容的平台.
研究的目的:
- 合成和表征黄素 (Cur) 和细菌外聚糖 (EPS) 的小细胞结合物.
- 评估Cur-EPS合物作为药物输送系统的制药潜力.
主要方法:
- 使用酸对Cur与EPS进行共价链接.
- 使用动态光散射 (DLS) 进行Cur-EPS合物的尺寸和多分散度指数 (PDI) 的表征.
- 在不同pH值 (酸性pH5.6和系统性pH7.4) 的体外释放动力学研究.
- 对骨髓瘤细胞 (MG-63) 的血液相容性,细胞毒性测定,抗菌,抗菌膜和抗氧化剂活性评估.
主要成果:
- 合成了具有平均水力动力直径为254nm的球状状Cur-EPS合物.
- 与自由电流相比,结合物表现出增强的稳定性 (负表面电荷,低PDI).
- 观察到pH响应的药物释放,在酸性pH (87.5%) 与系统性pH (30.15%) 之间,Cur释放显著更高.
- 库尔-EPS合物显示出血红相容性,对MG-63细胞的细胞毒性,以及优于自由库尔的抗菌,抗菌膜和抗氧化活性.
结论:
- 库尔-EPS合物代表了一种有前途的方法来提高黄素的生物可用性和治疗疗效.
- 响应pH的性质和增强的生物活性表明作为一种新型药物输送系统的潜在制药应用.
相关概念视频
Bioavailability Enhancement: Drug Solubility Enhancement
504
Bioavailability is a critical factor in determining a drug's effectiveness. It refers to the proportion of a drug that enters the circulation when introduced into the body and is, as a result, able to have an active effect. Enhancing bioavailability is essential for drugs with poor solubility, as it can significantly impact their therapeutic efficacy. Various methods are employed to increase the solubility of drugs, thereby enhancing their bioavailability.Micronization and nanonization are...
504
Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
336
Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
336
Modified-Release Drug Delivery Systems: Stimuli-Activated
184
Stimuli-activated drug delivery systems are designed to release drugs in response to specific physical, chemical, or biological stimuli. These systems often utilize hydrogels—three-dimensional, hydrophilic polymer networks capable of swelling in aqueous environments and retaining significant fluid volumes. Upon exposure to particular stimuli, these hydrogels undergo structural transitions that allow the embedded drug to be released. Due to this adaptive behavior, such systems are also...
184
Modified-Release Drug Delivery Systems: Site-Targeted
167
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
167
Site-Targeted Drug Delivery Systems: Polymeric Carriers
165
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
165


